On June 16, 2026, the U.S. Food and Drug Administration (FDA) approved Rextovy (naloxone hydrochloride 4 mg) nasal spray for over-the-counter (OTC) use in the emergency treatment of opioid overdose. See the full FDA announcement: https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose.
PEGUS Research was pleased to support this approval through summative human factors research. We congratulate Amphastar Pharmaceuticals, Inc. on this important achievement and commend the FDA’s continued leadership in advancing nonprescription access to critical therapies. PEGUS strongly supports the expansion of OTC naloxone as a vital tool in addressing the U.S. opioid crisis.
